EMERGENT BIOSOLUTIONS INC. Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax
EMERGENT BIOSOLUTIONS INC. (EBS) reported Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax of $0 for the 3-month period ending 2018-09-30, per its 10-Q filed 2019-11-07.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax · last filed 2019-11-07
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for the quarter ending 2018-09-30 was $0.00.
- EMERGENT BIOSOLUTIONS INC. other comprehensive income (loss), derivatives qualifying as hedges, net of tax for the quarter ending 2018-06-30 was $0.00.
| Period end | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 3 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 6 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax 9 month |
|---|---|---|---|
| 2018-09-30 | $0.00 10-Q · filed 2019-11-07 | $0.00 derived: sum of 2 quarters · filed 2019-11-07 | $0.00 10-Q · filed 2019-11-07 |
| 2018-06-30 | $0.00 10-Q · filed 2019-08-02 | $0.00 10-Q · filed 2019-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |